Dzhintropin - recombinant somatotropin hormone drug.
Structure and Composition Dzhintropina
Dzhintropin produced as a lyophilisate for solution for s / c administration at dosages of 4 IU and 10 IU, containing active substance - somatropin - at 1, 3 and 33 mg, 33 mg, respectively.
Auxiliary components of the formulation are sodium chloride, sodium dihydrogen phosphate, glycine and mannitol.
Dzhintropin available in vials complete with a disposable syringe and a solvent.
Pharmacological action Dzhintropina
Dzhintropin - genetically engineered growth hormone, which promotes physical and skeletal growth. Application Dzhintropina has a strong influence on the metabolic processes of the body. The drug stimulates the growth of bones, affecting the bone metabolism and epiphysis plates of long bones. Increases lean muscle mass, which helps normalize the body structure. In patients with growth hormone deficiency and osteoporosis, hormone therapy helps to normalize density and bone mineral composition.
According to the instructions, Dzhintropin also lowers cholesterol and stimulates the transport of amino acids into cells, and protein synthesis by affecting the profile of lipoproteins and lipids. It increases the size of muscle cells, thymus, liver, gonads, thyroid and adrenal glands. It inhibits the release of insulin. Delays in the body phosphorus, potassium and sodium. Increases physical stamina, muscle activity and body weight.
According to the instructions, prescribed to children under Dzhintropin stunted growth due to insufficient production of growth hormone by the body, with Turner's syndrome and chronic renal insufficiency (with reduced kidney function for more than 50% of normal) in puberty.
Adults Dzhintropin prescribed for acquired or congenital deficiency of growth hormone as a substitution treatment.
Dzhintropin contraindicated in the following cases:
- pregnancy and breastfeeding (in the case of Dzhintropina breastfeeding advisable to give);
- Active brain tumor;
- hypersensitivity to somatropin and additional components of the drug;
- depression (especially after surgeries on the heart and abdomen, with acute respiratory failure).
According to reviews, Dzhintropin should be used with caution in intracranial hypertension, diabetes mellitus, hypothyroidism.
Dosing and dosing regimen Dzhintropina
According to the instructions, Dzhintropin introduced n / a, slow, no more than once a day, usually at bedtime. To prevent occurrence of lipoatrophy should periodically change the site of injection.
The contents of the vial should be dissolved in 1 ml of solvent applied to the drug. To gain the solvent syringe and injected into the vial through the stopper. Stir until completely dissolved (without abrupt shaking). Ready solution can be stored at a temperature of 2-8 degrees is not more than 14 days.
The dosages for patients are selected individually depending on the severity of a lack of growth hormone, the body weight and efficacy.
In case of insufficient production of growth hormone in children, the dosage is 25-35 mg per kg body weight per day. Treatment should be assigned to the earliest possible age and continue until puberty or before the closing of the zone of bone growth. When the desired result of the treatment can be stopped.
When growth hormone deficiency in adults initial dosage Dzhintropina on instruction is 0, 15-0, 3 mg per day, and thereafter it is increased to achieve the desired effect.
When Turner's syndrome and chronic renal failure in children, which is accompanied by growth retardation, the recommended dose is 50 mg per kg body weight per day.
Acute overdose Dzhintropinom, reviews may lead initially to hypoglycemia and hyperglycemia after. In the case of long-term overdose observed symptoms characteristic of an excess of growth hormone in the body: gigantism, acromegaly, hypothyroidism, reducing the concentration of serum cortisol.
In case of overdose the drug should be discontinued and a symptomatic treatment.
According to reviews, Dzhintropin can cause side effects such as increased intracranial pressure, hyperglycemia, decreased thyroid function, epiphysiolysis femoral head leukemoid reactions, myalgia, arthralgia, water retention in the body with the development of peripheral edema, carpal tunnel syndrome.
As a rule, all of the above symptoms are dozozivisimy nature and disappear after dose adjustment.
There may be allergic reactions such as itching and skin rash. Very rarely in the body can be formed to a preparation of antibody, which decreases its effectiveness.
Local reactions to the use of Dzhintropina may include: itching, pain, swelling, redness and lipoatrophy at the injection site.
Interaction Dzhintropina with other drugs
The stimulating effect of growth hormone on growth hormones reduce SCS.
Affect the efficiency of the drug may simultaneous treatment other hormones (gonadotropin, estrogens, anabolic steroids, thyroid hormones).
The preparation is stored in a dark place at a temperature of 2-8 degrees. Ready solution should not be stored longer than 14 days. Dzhintropin refers to prescription drugs with a recommended shelf life - 24 months.